Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...

This disease is primarily treated with off-label drugs or newer meds in the form of GSK's Benlysta and AstraZeneca's Saphnelo. The most common form of the disease is systemic lupus erythematosus ...

with newer medicines like GSK's Benlysta (belimumab), AstraZeneca's Saphnelo (anifrolumab), and Otsuka's Lupkynis (voclosporin). For Biogen, dapirolizumab pegol is part of a push into the ...

Patients with radiographic axial spondyloarthritis who receive ixekizumab biweekly demonstrate lower sacroiliac joint erosion and increased the backfill of new tissue through 52 weeks, according ...

At close: March 26 at 5:29:51 PM GMT+1 Loading Chart for AZN.ST ...